PROMISE-EPI study started in Zambia in December 2019.
The First Patient First Visit (FPFV) occurred on December 12th. The study was first initiated in 3 sites in Lusaka (Chilenje, Bauleni and Matero Main) and a new site (Chaisa) was opened in the capital in the end of March 2020. One year inclusion period is planned. More information on the study design are available on our web site and on clinicaltrials.gov
In Burkina Faso the approval from the National Ethic Committee was received on 06th May 2020. The next step is now the submission to the Competent Authority (ANRP).